Tempest Therpeutics Inc (TPST)

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”...

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with...

Form 8-K - Current report

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003...

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T...

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables...